Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emeramide in COPD
NCT03123692Phase 2Completed
- Sponsor
- EmeraMed
- Start
- Jan 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of emeramide in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by EmeraMed. Primary endpoint: Safety and tolerability - Adverse events at 14 days. Started Jan 2017; status: completed.
02
Drugs
emeramide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03123692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03123692.